Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Theravance Biopharma, Inc. Director's Dealing 2021

Feb 24, 2021

32537_dirs_2021-02-23_24f50d80-96ad-4403-a167-87b07fed7dc7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Theravance Biopharma, Inc. (TBPH)
CIK: 0001583107
Period of Report: 2021-02-20

Reporting Person: PASQUALONE FRANK (SVP, Chief Business Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-20 Ordinary Shares F 26961 $18.79 Disposed 439719 Direct